Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
COVID-19 inactive vaccine + recombinant human adenovirus serotype number 26 + mRNA vaccine-Karamanoğlu Mehmetbey University-COVID-19
- Development stage
- Unknown
- Lead developer
- Sinovac Biotech
- Modality
- Recombinant Proteins and Enzymes, mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
This entry refers to a comparative clinical evaluation of three distinct COVID-19 vaccine platforms: an inactivated virus vaccine (CoronaVac), a recombinant human adenovirus serotype 26 vector vaccine (Sputnik V), and an mRNA-based vaccine (BNT162b2). Conducted by Karamanoğlu Mehmetbey University (NCT05061290), the study assesses the long-term persistence of Anti-SARS-CoV-2 IgG and neutralizing antibodies at 2, 6, and 12 months following the second dose. The combination represents the diverse technological approaches—inactivated whole virus, viral vector-mediated antigen expression, and lipid nanoparticle-delivered mRNA—used to elicit protective immunity against the SARS-CoV-2 spike protein and other viral components in a multi-center Turkish population.
- Brand names
- CoronaVacSputnik VComirnaty
- Other names
- Sinovac COVID-19 vaccineGam-COVID-VacPfizer-BioNTech COVID-19 vaccine
02
Targets
SARS-CoV-2 spike
Beyond the preview
Go deeper on COVID-19 inactive vaccine + recombinant human adenovirus serotype number 26 + mRNA vaccine-Karamanoğlu Mehmetbey University-COVID-19.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on COVID-19 inactive vaccine + recombinant human adenovirus serotype number 26 + mRNA vaccine-Karamanoğlu Mehmetbey University-COVID-19.